Predictors of Hypothyroidism Following Empirical Dose Radioiodine in Toxic Thyroid Nodules: Real-Life Experience

Basit Öğe Kaydı
dc.authoridKARAKILIC, ERSEN/0000-0003-3590-2656
dc.authoridSAYGILI, Emre Sedar/0000-0003-0022-5704
dc.contributor.authorDemir, Busra Kuyumcu
dc.contributor.authorKarakilic, Ersen
dc.contributor.authorSaygili, Emre Sedar
dc.contributor.authorAraci, Nilgun
dc.contributor.authorOzdemir, Semra
dc.date.accessioned2025-01-27T20:38:45Z
dc.date.available2025-01-27T20:38:45Z
dc.date.issued2022
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractObjective: We aimed to determine the factors predicting hypothyroidism after radioactive iodine (RAI) treatment in patients with toxic adenoma and toxic multinodular goiter.Methods: We retrospectively collected the data of 237 patients with toxic multinodular goiter or toxic adenoma who had consecutively received RAI treatment between 2014 and 2020 at 2 medical centers. Patients who received the second RAI treatment and whose medical records could not be accessed were excluded from the study. Finally, 133 patients were included in the study. RAI was administered at an empirical dose of 15 or 20 mCi.Results: The median age of the 133 participants was 69 years (interquartile range, 62-75 years), and 64.7% of the participants were women. A total of 42.1% of the patients had toxic adenoma, whereas 57.9% of patients had toxic multinodular goiter. The median follow-up was 24 months (interquartile range, 11-38 months). During the follow-up, 61.7% of patients became euthyroid, 30.8% developed hypothy-roidism, and 7.5% remained hyperthyroid. The median month of hypothyroidism onset was 4 months (interquartile range, 2-9 months). Regression analysis revealed 2 factors that could predict hypothy-roidism: thyroid-stimulating hormone (odds ratio, 2.548; 95% CI, 1.042-6.231; P = .04) and thyroid volume (odds ratio, 0.930; 95% CI, 0.885-0.978; P = .005).Conclusion: Overall, 30.8% of the cases developed hypothyroidism after the RAI treatment. Approxi-mately 78% of hypothyroidism developed within the first 10 months. The risk of hypothyroidism was higher in patients with higher thyroid-stimulating hormone and smaller thyroid volume.(c) 2022 AACE. Published by Elsevier Inc. All rights reserved.
dc.identifier.doi10.1016/j.eprac.2022.05.001
dc.identifier.endpage753
dc.identifier.issn1530-891X
dc.identifier.issn1934-2403
dc.identifier.issue8
dc.identifier.pmid35537668
dc.identifier.scopus2-s2.0-85135342279
dc.identifier.scopusqualityQ1
dc.identifier.startpage749
dc.identifier.urihttps://doi.org/10.1016/j.eprac.2022.05.001
dc.identifier.urihttps://hdl.handle.net/20.500.12428/23738
dc.identifier.volume28
dc.identifier.wosWOS:000863129700003
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier Inc
dc.relation.ispartofEndocrine Practice
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20250125
dc.subjecthyperfunctioning
dc.subjecthyperthyroidism
dc.subjecthypothyroidism
dc.subjectiodine-131
dc.subjectthyroid adenoma
dc.titlePredictors of Hypothyroidism Following Empirical Dose Radioiodine in Toxic Thyroid Nodules: Real-Life Experience
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu